AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04649359
Drug: Elranatamab (PF-06863135)
RxNorm normalized name: elranatamab
DrugBank: Elranatamab (DB15395)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCMA-CD3 bispecific antibody
Trial: NCT05325632
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8mg/kg IV Trastuzumab will be given week 1, followed by 6 mg/kg on subsequent cycles every 3 weeks
Trial: NCT05325632
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 840 mg IV Pertuzumab will be given week 1, followed by 420 mg on subsequent cycles every 3 weeks.
Trial: NCT05325632
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg/m\^2 IV paclitaxel will be given weekly weeks 7-18
Trial: NCT06044740
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After a no-drug control period, subjects will inhale sevoflurane, administered via a breathing circuit and face mask, until a steady-state target end-tidal expired concentration of 0.4% (corresponding to 0.2 Minimum Alveolar Concentration) is reached.
Trial: NCT06219941
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy agents
Trial: NCT06219941
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy agents
Trial: NCT06219941
Drug: Nanoliposomal Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy agents
Trial: NCT06219941
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy agents
Trial: NCT05192200
Drug: Anti-Beta Interferon (PF-06823859)
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT05027958
Drug: Tuberculin Purified Protein Derivative
RxNorm normalized name: Tuberculin Purified Protein Derivative
DrugBank: Tuberculin purified protein derivative (DB11601)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPD administered through the airways to elicit the development of alveolar inflammation challenge dose of 0.5 TU
Trial: NCT05200481
Drug: Brigatinib 180 MG
RxNorm normalized name: brigatinib 180 MG
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive brigatinib orally at a dose of 90 mg QD for a 7 days lead-in period followed by 180 mg QD continuously, with or without food, in 28-day cycles until progression. Dose reductions are possible.
Trial: NCT05200481
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive pemetrexed 500 mg/m² followed by carboplatin to target AUC of 5 mg/mL/min both on Day 1 as IV infusion every 3 weeks for 4 infusions. The first infusion of carboplatin and pemetrexed will be administrated at day 8 of brigatinib treatment, at time of dose escalation from 90 mg QD to 180mg QD continuously.
Trial: NCT05200481
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive pemetrexed 500 mg/m² followed by carboplatin to target AUC of 5 mg/mL/min both on Day 1 as IV infusion every 3 weeks for 4 infusions. The first infusion of carboplatin and pemetrexed will be administrated at day 8 of brigatinib treatment, at time of dose escalation from 90 mg QD to 180mg QD continuously.
Trial: NCT05287113
Drug: Retifanlimab
RxNorm normalized name: Retifanlimab
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retifanlimab 500mg will be administered intravenously every 4 weeks.
Trial: NCT05287113
Drug: INCAGN02385
RxNorm normalized name: Anti-LAG-3 Monoclonal Antibody INCAGN02385
DrugBank: Tuparstobart (DB19118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCAGN02385 350mg will be administered intravenously every 2 weeks.
Trial: NCT05287113
Drug: INCAGN02390
RxNorm normalized name: INCAGN02390
DrugBank: Verzistobart (DB18895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCAGN02390 400 mg will be administered intravenously every 2 weeks.
Trial: NCT05192798
Drug: Albumin-Bound Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Albumin-bound paclitaxel is one of the standard first-line regimens for relapsed or metastatic triple-negative breast cancer.
Trial: NCT05192798
Drug: Apatinib Mesylate
RxNorm normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib mesylate is an orally administered small-molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor (TKI).
Trial: NCT05192798
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab is a humanized anti-VEGF monoclonal antibody once approved by FDA for treatment of metastatic breast cancer in combination with chemotherapy.
Trial: NCT05266807
Drug: oral capsulized Fecal Microbiota Transplantation
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMT will be administered per os in the form of capsules containing faeces from a healthy donor. Capsules are manufactured at the CHUV pharmacy (University Hospital of Lausanne, Switzerland)
Trial: NCT05266807
Drug: Vancomycin or Fidaxomicin
RxNorm normalized name: Fidaxomicin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vancomycin or Fidaxomicin per os as initially prescribed per SoC
Trial: NCT05845398
Drug: DCR-AUD
RxNorm normalized name: DCR-PHXC free acid
DrugBank: Nedosiran (DB17635)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCR-A1203, the drug substance of DCR-AUD, is a synthetic double-stranded (hybridized duplex) RNA oligonucleotide conjugated to GalNAc ligands that enable specific hepatic access and update after subcutaneous administration. DCR-AUD is a sterile solution of DCR-A1203 at a concentration of 160 mg/mL in water for injection (WFI).
Trial: NCT04495959
Drug: 68Ga-HTK03149
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET/MRI scan with radiotracer 68Ga-HTK03149
Trial: NCT05161481
Drug: Avenciguat (BI 685509)
RxNorm normalized name: Avenciguat
DrugBank: Avenciguat (DB18882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avenciguat (BI 685509)
Trial: NCT04730414
Drug: Full-spectrum hemp (0.018% THC)
RxNorm normalized name: hemp
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical Application
Trial: NCT05161481
Drug: Placebo matching Avenciguat (BI 685509)
DrugBank: Avenciguat (DB18882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching Avenciguat (BI 685509)
Trial: NCT05203939
Drug: OCU400 Low Dose
RxNorm normalized name: ethinyl estradiol
DrugBank: OCU400 (DB18277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subretinal injection of up to 1.66 × 10\^10 vg/mL
Trial: NCT05203939
Drug: OCU400 Med Dose
RxNorm normalized name: OCU400
DrugBank: OCU400 (DB18277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subretinal injection of upto 3.33 × 10\^10 vg/mL
Trial: NCT05203939
Drug: OCU400 High Dose
RxNorm normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: OCU400 (DB18277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subretinal injection of upto 1.66 × 10\^11 vg/mL
Trial: NCT06295731
Drug: INBRX-106
RxNorm normalized name: INBRX-101
DrugBank: INBRX-101 (DB18384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INBRX-106 by intravenous (IV) infusion, given every 3 weeks (QW3)
Trial: NCT06295731
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200 mg by intravenous (IV) infusion, given every 3 weeks (QW3)
Trial: NCT05425576
Drug: OT-101
RxNorm normalized name: OT-730
DrugBank: OT-730 (DB16112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OT-101 in combination of pembrolizumab
Trial: NCT06524635
Drug: Lutikizumab
RxNorm normalized name: Lutikizumab
DrugBank: Lutikizumab (DB16224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) Injection
Trial: NCT05620823
Drug: Povorcitinib
RxNorm normalized name: Povorcitinib
DrugBank: Povorcitinib (DB18855)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral; Tablet
Trial: NCT06630494
Drug: Recombinant human thrombopoietin for injection (rhTPO)
RxNorm normalized name: hyaluronidase, human recombinant Injection
DrugBank: Thrombopoietin (DB06534)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single abdominal subcutaneous injection of the study drug will be given on D1. The administration and follow-up observation period will be 29 days (D1\~D29). Participants may be discharged at D7 at the judgment of the investigator. PK blood samples will be collected from D-1 to D14, tolerance and safety will be observed from D1 to D29, and blood samples for PD and anti-drug antibody (ADA) will be collected from screening to D29. After completion of relevant assessments on D29, participants will be considered as having completed this study.
Trial: NCT06410859
Drug: Botulinum Toxin Type A for Injection,also known as HengLi®
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: This study plans to enroll 240 subjects, and the efficacy measures \[VAS score, DSIS score, daily pain duration (if applicable), and number of daily pain episodes\] will be collected from subjects using the electronic Patient-Reported Outcomes (ePRO) throughout the study. The study period mainly consists of a screening period (14 days before the first dose), a double-blind treatment period (from the first dose to Week 12), and an extension period (from Week 13 to Week 52), including a maximum of 4 treatment cycles (each cycle lasts 12 week)
Trial: NCT06364930
Drug: Dapagliflozin 10mg Tab
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin 10mg Tab QD for 60 months.
Trial: NCT06567587
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Effect o dexmedetomine on agitated normal and psychotic patients on BIPAP who are suffer exaggerated COPD
Trial: NCT06150040
Drug: NP137
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion, 14mg/kg or 9mg/kg, every 2 weeks
Trial: NCT06150040
Drug: Azacitidine Injection
RxNorm normalized name: azacitidine Injection
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous injection, 75 mg/m², on cycle Days 1-7 (28-days cycle)
Trial: NCT06150040
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Orally, 70 mg, every day on Days 1-28
Trial: NCT05147220
Drug: Remibrutinib
RxNorm normalized name: Remibrutinib
DrugBank: Remibrutinib (DB16852)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet taken orally
Trial: NCT05147220
Drug: Teriflunomide
RxNorm normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: capsule taken orally
Trial: NCT06567314
Drug: Ivonescimab
RxNorm normalized name: Ivonescimab
DrugBank: Ivonescimab (DB18931)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT06450041
Drug: Universal Donor (UD) TGFβi NK Cells
RxNorm normalized name: iobenguane I-131
DrugBank: Iobenguane (DB06704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a dose of 1x108 UD TGFβi NK cells/kg per treatment cycle on day 8 of each cycle
Trial: NCT06450041
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enteral or IV daily on days 1-5 of each cycle For patients ≥ 0.5 m2: 100 mg/m2/dose For patients \< 0.5 m2: 3.3 mg/kg/dose MAXIMUM dose = 200 mg
Trial: NCT06450041
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50mg/m2/dose IV daily on days 1-5 of each cycle
Trial: NCT06450041
Drug: Dinutuximab
RxNorm normalized name: Dinutuximab
DrugBank: Dinutuximab (DB09077)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 17.5mg/m2/dose IV daily on days 2-5 of each cycle
Trial: NCT06450041
Drug: GM-CSF
RxNorm normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250mcg/m2/dose subcutaneous (preferred) or IV daily on days 6-12 of each cycle
Trial: NCT04665037
Drug: Posaconazole IV 6 mg/kg
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: POS 6 mg/kg body weight by IV infusion
Trial: NCT06159686
Drug: Hemp
RxNorm normalized name: Hemp
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The application of the hemp-containing cream occurred in the morning and evening on the itching areas, excluding the face for 4 weeks.
Trial: NCT05588323
Drug: Naldemedine
RxNorm normalized name: Naldemedine
DrugBank: Naldemedine (DB11691)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered as an oral tablet (0.2 mg dose level only), or oral suspension (all dose levels)
Trial: NCT05636293
Drug: Ritlecitinib
RxNorm normalized name: Ritlecitinib
DrugBank: Ritlecitinib (DB14924)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg Ritlecitinib
Trial: NCT06541691
Drug: Enteric-coated aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-coated aspirin tablet 81 mg, once daily
Trial: NCT06305598
Drug: Leuprolide Acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given SC
Trial: NCT06305598
Drug: Testosterone Cypionate
RxNorm normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IM
Trial: NCT05891496
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Semagllutide will be administered once weekly subcutaneously.
Trial: NCT06568302
Drug: SerpinPC
RxNorm normalized name: SerpinPC
DrugBank: SerpinPC (DB17698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as SC injection.
Trial: NCT04750473
Drug: Fluciclovine F18
RxNorm normalized name: FLUCICLOVINE F18 (9-221 MCI/ML) INJ
DrugBank: Fluciclovine (18F) (DB13146)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04750473
Drug: Gallium Ga 68 Gozetotide
RxNorm normalized name: LOCAMETZ Kit for the Preparation of Gallium Ga 68 Gozetotide Injection
DrugBank: Gallium nitrate (DB05260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06465563
Drug: SHR-8068
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-8068
Trial: NCT06465563
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebrelimab
Trial: NCT06465563
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin
Trial: NCT06465563
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine
Trial: NCT06456359
Drug: Signifor
RxNorm normalized name: Signifor
DrugBank: Pasireotide (DB06663)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Signifor 40 mg: each vial contains 40 mg pasireotide (as pasireotide pamoate). Signifor 60 mg: each vial contains 60 mg pasireotide (as pasireotide pamoate).
Trial: NCT04874480
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04874480
Drug: Tegavivint
RxNorm normalized name: Tegavivint
DrugBank: Tegavivint (DB17109)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00008866
Drug: Hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00008866
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04533347
Drug: Tafenoquine Oral Tablet
RxNorm normalized name: tafenoquine Oral Tablet
DrugBank: Tafenoquine (DB06608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and 10.
Trial: NCT06491563
Drug: BRII-835 (VIR-2218)
RxNorm normalized name: tick-borne encephalitis purified antigen
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRII-835 will be given via subcutaneous injection
Trial: NCT05783609
Drug: Epcoritamab
RxNorm normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-cell bispecific antibody, via subcutaneous injection
Trial: NCT05783609
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chimeric anti-CD20 monoclonal antibody, via IV infusion
Trial: NCT04635098
Drug: dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All participants will be randomly assigned to receive either dexmedetomidine or saline
Trial: NCT04635098
Drug: saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants will be randomly assigned to receive either dexmedetomidine or saline
Trial: NCT04986605
Drug: UVADEX
RxNorm normalized name: Uvadex
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The phase II aspect of the study refers to the drug, methoxsalen. Methoxsalen is being used off label from the currently approved indications in the monograph. The study is proposing to use methoxsalen in combination with with extracorporeal photopheresis for the treatment of diffuse cutaneous systemic sclerosis. Treatment will be given in addition to standard of care medications for SSc.
Trial: NCT05638672
Drug: Monapiravir
RxNorm normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Monapiravir, manufactured by Merck, an American pharmaceutical company, with the specification of 200mg × 40 capsules, 800mg each time, twice a day.
Trial: NCT05294588
Drug: Cefixime
RxNorm normalized name: Cefixime
DrugBank: Cefixime (DB00671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mandatory rescue therapy consisting of cefixime 400 mg orally in a single dose: on patient request, at the onset of clinically apparent urethritis or on the 10th study day after inoculation.
Trial: NCT05294588
Drug: Ceftriaxone
RxNorm normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mandatory rescue therapy consisting of ceftriaxone 250 mg intramuscularly in a single dose: on patient request, at the onset of clinically apparent urethritis or on the 10th study day after inoculation.
Trial: NCT05294588
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mandatory antibiotic treatment failure therapy: Ciprofloxacin 500 mg orally in a single dose: if the subject has a positive N. gonorrhoeae test within 1 week post initial antibiotic treatment
Trial: NCT06457204
Drug: Pramipexole (from manufacturing site 2)
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pramipexole (from manufacturing site 2) - reference treatment
Trial: NCT06189781
Drug: Ropivacaine injection
RxNorm normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The local anesthetic group will be injected with ropivacaine 2mg/mL (3mg/kg), epinephrine 1mg/mL (0.5mg), and ketorolac 30mg/mL (0.5mg/kg). The maximum dose of ropivacaine regardless of patient weight will be 200mg. This is based on recommended maximum dose protocols from our anesthesia colleagues. If bilateral hips are involved, the total amount will be split evenly between the two sides.
Trial: NCT06189781
Drug: Bupivacaine, lidocaine, ropivacaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The lumbar epidural group will receive a combination of either/or bupivacaine, lidocaine, and ropivacaine, which will be monitored by the anesthesia team.
Trial: NCT05706454
Drug: Ramatroban
RxNorm normalized name: Ramatroban
DrugBank: Ramatroban (DB13036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Route of Administration: Oral Dose: 75 mg; Frequency: Twice daily; Total duration of intervention: 28 days.~Subjects will be evaluated over a study period of approximately 365 days.
Trial: NCT06700408
Drug: Dachaihu Decoction combined Erzhiwan with variation
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chinese medicine granules
Trial: NCT06206811
Drug: OD-07656
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: innate immune modulator
Trial: NCT06158399
Drug: Azacitidine in combination with R-CHOP
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified dose on specified days:~Azacitidine (A) 100mg subcutaneous d-1 to d-5 Rituximab (R) 375mg/m2 IV d0 Cyclophosphamide (C) 750mg/m2 IV d1 epirubicin (H) 75mg/m2 IV d1 or liposomal adriamycin (D) 25-30mg/m2 IV d1 Vincristine (O) 1.4mg/m2 (max 2mg) IV d1 Prednisone (P) 100mg orally d1-5